Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myasthenia Gravis 1Multiple Myeloma 1Leukemia 1Infections 1Graft vs Host Disease 1Cancer Therapy-related Cardiovascular Toxicity 1Burkitt Lymphoma 1Arthritis, Rheumatoid 1

Interventions

Cyclophosphamide 37Cytarabine 27Methotrexate 22Dexamethasone 20Vincristine 19fludarabine 15Mercaptopurine 14Etoposide 14Radiotherapy 12Daunorubicin 12Asparaginase 12Doxorubicin 11Prednisolone 9Idarubicin 9Busulfan 8pegaspargase 7blinatumomab 7Peripheral Blood Stem Cell Transplantation 6Melphalan 6Immunotherapy, Adoptive 6Imatinib Mesylate 6Dasatinib 6fludarabine phosphate 5Prednisone 5Methylprednisolone 5Filgrastim 5Whole-Body Irradiation 4Thioguanine 4Rituximab 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Precursor Cell Lymphoblastic Leukemia-Lymphoma × tocilizumab × Clear all
NCT03467256 2023-02-24

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 1/2 Unknown
18 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡